Safety and Efficacy of AZD0120, a BCMA/CD19 Dual-Targeting CAR T-cell Therapy, in relapsed/refractory Multiple Myeloma: Preliminary Results from the DURGA-1 phase 1b/2 Study

Key Points

AZD0120 shows potential efficacy in treating relapsed/refractory multiple myeloma, enhancing therapeutic options.
Safety assessments reveal manageable adverse effects in the observed cohort of treated individuals.
This phase 1b/2 study explores changes from prior therapies, revealing new response patterns to the dual-targeting approach.
The findings may support further clinical trials and development of advanced CAR T-cell therapies for multiple myeloma.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Preliminary results show safety and efficacy of AZD0120 CAR T-cell therapy in relapsed/refractory multiple myeloma, indicating promise for treatment.

No takes yet. Share an insight, caveat, or question.

Firpo et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share